{"id":29843,"date":"2016-03-22T09:12:09","date_gmt":"2016-03-22T09:12:09","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=29843"},"modified":"2016-03-22T09:52:04","modified_gmt":"2016-03-22T09:52:04","slug":"eu-adopts-positive-opinion-on-dual-formulation-of-ftaf","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/29843","title":{"rendered":"EU adopts positive opinion on dual formulation of F\/TAF"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>On 26 February 2016, Gilead Sciences issued a press release reporting that the scientific committee of the European Medicines Agency (EMA) had adopted a positive opinion for the new dual NRTI combination of emtricitabine (FTC) plus tenofovir alafenamide (TAF).<\/strong><\/p>\n<p>A positive opinion is usually sufficient for a drug to be approved by the European Commission, with the final decision expect by the third quarter of 2016.<\/p>\n<p>The formulation uses 200 mg of FTC with two doses available for TAF: 25 mg and 10 mg.<\/p>\n<p>Despite the Gilead press release, this is not a fixed dose combination because F\/TAF needs to be taken in combination with other additional drugs.<\/p>\n<p>F\/TAF is manufactured by Gilead and will have the tradename Descovy.<\/p>\n<p>Reference:<\/p>\n<p>Gilead PR. European CHMP adopts positive opinion for Gilead&#8217;s fixed-dose combination Descovy (emtricitabine\/tenofovir alafenamide) for the treatment of HIV (26 February 2016).<br \/>\n<a href=\"http:\/\/www.gilead.com\/news\/press-releases\/2016\/2\/european-chmp-adopts-positive-opinion-for-gileads-fixeddose-combination-descovy-emtricitabinetenofovir-alafenamide-for-the-treatment-of-hiv\">http:\/\/www.gilead.com\/news\/press-releases\/2016\/2\/european-chmp-adopts-positive-opinion-for-gileads-fixeddose-combination-descovy-emtricitabinetenofovir-alafenamide-for-the-treatment-of-hiv<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base On 26 February 2016, Gilead Sciences issued a press release reporting that the scientific committee of the European Medicines Agency (EMA) had adopted a positive opinion for the new dual NRTI combination of emtricitabine (FTC) plus &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-29843","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=29843"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29843\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=29843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=29843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=29843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}